Rapid Micro Biosystems (NASDAQ:RPID) Downgraded to Sell Rating by Wall Street Zen

Key Points

• Rapid Micro Biosystems has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, while Lake Street Capital has recently initiated coverage with a "buy" rating and an $8.00 price target.
• The company's stock saw a 6.3% increase on Friday, opening at $2.85, with a 52-week range between $0.80 and $4.50.
• In its latest earnings report, Rapid Micro Biosystems missed EPS estimates, reporting ($0.27) against a consensus of ($0.26), despite exceeding revenue expectations at $7.26 million.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Friday.

Separately, Lake Street Capital initiated coverage on shares of Rapid Micro Biosystems in a research report on Monday, July 28th. They set a "buy" rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Strong Buy" and a consensus price target of $8.00.

Rapid Micro Biosystems Price Performance

RPID stock traded down $0.05 during trading on Friday, reaching $2.51. 71,523 shares of the company were exchanged, compared to its average volume of 95,176. The company has a 50-day moving average of $3.29 and a two-hundred day moving average of $2.98. The company has a market capitalization of $110.97 million, a price-to-earnings ratio of -2.49 and a beta of 1.32. Rapid Micro Biosystems has a twelve month low of $0.80 and a twelve month high of $4.50.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.01). The company had revenue of $7.26 million for the quarter, compared to analyst estimates of $7.10 million. Rapid Micro Biosystems had a negative return on equity of 63.07% and a negative net margin of 145.63%. Rapid Micro Biosystems has set its FY 2025 guidance at EPS. On average, analysts forecast that Rapid Micro Biosystems will post -1.1 EPS for the current year.

Insiders Place Their Bets

In other Rapid Micro Biosystems news, CEO Robert G. Jr. Spignesi sold 11,881 shares of the business's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $3.32, for a total transaction of $39,444.92. Following the sale, the chief executive officer directly owned 970,550 shares of the company's stock, valued at $3,222,226. The trade was a 1.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders have sold 57,443 shares of company stock worth $195,952. Insiders own 29.96% of the company's stock.

Institutional Investors Weigh In On Rapid Micro Biosystems

A number of institutional investors have recently modified their holdings of RPID. ABG WTT Global Life Science Capital Partners GP Ltd boosted its stake in shares of Rapid Micro Biosystems by 78.0% in the 1st quarter. ABG WTT Global Life Science Capital Partners GP Ltd now owns 1,848,296 shares of the company's stock valued at $4,880,000 after purchasing an additional 810,000 shares during the last quarter. Parkman Healthcare Partners LLC bought a new stake in shares of Rapid Micro Biosystems in the 1st quarter valued at $1,942,000. Informed Momentum Co LLC bought a new stake in shares of Rapid Micro Biosystems in the 1st quarter valued at $467,000. Evernest Financial Advisors LLC bought a new stake in shares of Rapid Micro Biosystems in the 1st quarter valued at $347,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Rapid Micro Biosystems in the 1st quarter valued at $289,000. 52.60% of the stock is owned by institutional investors.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.